STAT Plus: Pharmalittle: Thousands sign up for trials studying hydroxycholoroquine; Gilead drug fails to help Covid-19 patients
And so, another working week will soon draw to a close. This may be hard to tell for those of you now spending all your time at home, but the pages on the calendar are still turning. So please join us as we begin our weekly ritual of daydreaming about weekend plans. Our agenda is rather modest. We expect to putter around the castle, get lost in a book, train our new official mascot to behave, and maybe do the laundry. And what about you? This may be a good time to catch up on paperwork, check your pantry, and touch base with folks who might like to hear a friendly voice. Well, whatever you do, keep on the sunny side, but be safe. See you soon.
The antiviral medicine remdesivir from Gilead Sciences (GILD) failed to speed the improvement of patients with Covid-19 or prevent them from dying, STAT reports, citing results from a long-awaited clinical trial conducted in China. Gilead, however, argued the data suggest a “potential benefit.” A summary of the study results was inadvertently posted to the website of the World Health Organization and seen by STAT on Thursday, but then removed.
